EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study

Makoto Tahara, Richard Greil, Danny Rischin, Kevin J Harrington, Barbara Burtness, Gilberto de Castro, Amanda Psyrri, Irene Braña, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G M Hughes und 8 weitere

European Journal of Cancer · 2025-05 · 221 · 115395

DOI: 10.1016/j.ejca.2025.115395 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025-05. Verfasst von Makoto Tahara und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: matahara@east.ncc.go.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Squamous Cell Carcinoma of Head and Neck, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedSquamous Cell Carcinoma of Head and NeckAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHead and Neck NeoplasmsAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedFollow-Up StudiesAgedAdultCetuximabNeoplasm MetastasisProgression-Free Survival

Stichwörter der Autor:innen

ChemotherapyPembrolizumabProgrammed cell death ligand 1Recurrent/metastatic head and neck squamous cell carcinoma

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedCetuximabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: matahara@east.ncc.go.jp.
  • Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Salzburg, Austria.
  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
  • The Institute of Cancer Research, London, United Kingdom.
  • Yale School of Medicine, New Haven, CT, USA.
  • Instituto do Câncer de São Paulo-ICESP, São Paulo, Brazil.

Zitieren

APA

Tahara, M., Greil, R., Rischin, D., Harrington, K. J., Burtness, B., de Castro, G., Psyrri, A., Braña, I., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Ishak, W. Z. W., Lin, J., Gumuscu, B., Lerman, N., & Soulières, D. (2025). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. European Journal of Cancer, 221, 115395. https://doi.org/10.1016/j.ejca.2025.115395

Vancouver

Tahara M, Greil R, Rischin D, Harrington KJ, Burtness B, de Castro G, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. European Journal of Cancer. 2025;221:115395. doi:10.1016/j.ejca.2025.115395

BibTeX
@article{Tahara2025,
  author = {Tahara, Makoto and Greil, Richard and Rischin, Danny and Harrington, Kevin J and Burtness, Barbara and de Castro, Gilberto and Psyrri, Amanda and Braña, Irene and Neupane, Prakash and Bratland, Åse and Fuereder, Thorsten and Hughes, Brett G M and Mesía, Ricard and Ngamphaiboon, Nuttapong and Rordorf, Tamara and Ishak, Wan Zamaniah Wan and Lin, Jianxin and Gumuscu, Burak and Lerman, Nati and Soulières, Denis},
  title = {Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {221},
  pages = {115395},
  doi = {10.1016/j.ejca.2025.115395}
}
Kostenlos starten →